Nymox NX-1207 Symposium May 5 in San Diego at Annual Meeting of American Urological Association at San Diego Convention Center
April 30 2013 - 11:02AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to
announce further information about the upcoming Symposium on
NX-1207 to be held on May 5 at 3 p.m. in San Diego at the Annual
Meeting of the American Urological Association at the San Diego
Convention Center. The symposium is entitled, "Clinical studies of
NX-1207: Phase 3 Injectable for BPH (Phase 2 for Prostate Cancer),"
and will be held at the ICU Theater, Science and Convention Hall
#2233 at the Convention Center.
The Symposium will provide news and updates on Nymox's Phase 3
Studies of NX-1207 for BPH and its Phase 2 Study of NX-1207 for
Prostate Cancer, and will also provide information about safety,
immunological testing, and other scientific advances for the new
drug.
The keynote presentation will be given by Ronald Tutrone Jr, MD.
Dr. Tutrone is the Medical Director of Chesapeake Urology Research
Associates located in Baltimore, MD as well as the Chief of Urology
at the Greater Baltimore Medical Center. Panel members at the
Symposium will include Dr. Mohamed Bidair of San Diego CA, Dr.
Susan J. Kalota of Tucson AZ, Dr. Franklin D. Gaylis of San Diego
CA, Dr. Sheldon Freedman of Las Vegas, NV, Dr. Eugene Dula of
Tarzana, CA, and Dr. Michael T. Gambla of Columbus OH.
Dr. Bidair is Assistant Clinical Professor at the University of
California, San Diego and the Medical Director of San Diego
Clinical Trials, San Diego, CA. Dr. Kalota is a highly experienced
investigator at Urological Associates of Southern Arizona, Tucson,
AZ. Dr. Gaylis is the Medical Director of Genesis Research at
Genesis Healthcare Partners and Medical Director of the Clinical
Outcomes Improvement Program at Sharp Grossmont Hospital, San
Diego, CA. Dr. Freedman is a well known urologist and Medical
Director of Sheldon J. Freedman, MD, Ltd, Las Vegas, NV. Dr. Dula
is the Medical Director of West Coast Clinical Research and is a
partner at the San Fernando Valley Urological Associates, Tarzana,
CA. Dr. Gambla is President of Central Ohio Urology Group,
Columbus, OH, an investigator with Columbus Urology Research, and
Assistant Director of Urogynecology and Voiding Dysfunction at the
Riverside Methodist Hospital, Columbus, Ohio.
NX-1207 is a novel patented drug developed by Nymox which is
currently in late stage Phase 3 trials for benign prostatic
hyperplasia (BPH) and Phase 2 for localized prostate cancer.
NX-1207 is injected into the sector of prostate to be treated by a
urologist in a clinic setting. The procedure does not require
catheterization, anesthesia, or sedation, takes only a few minutes
and involves little or no pain or discomfort to the patient. In
multi-center U.S. clinical trials for BPH to date, a single dose of
NX-1207 has been found to produce on average symptomatic
improvements about double that reported for currently approved BPH
drugs without causing the sexual or cardiovascular side effects
associated with those drugs. Follow-up studies have shown evidence
of long lasting benefit with a significant proportion of men who
received a single dose reporting maintained improvement in BPH
symptoms without other treatments for up to 7½ years.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024